

MATERIAL SUPLEMENTARIO

Tabla 1. Estrategia de búsqueda para revisiones sistemáticas y meta-análisis en Medline.

#	Términos de la búsqueda	Citas
1	exp arthritis, rheumatoid/	52.700
2	((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.	73.319
3	(felty\$ adj2 syndrome).tw.	177
4	(caplan\$ adj2 syndrome).tw.	20
5	(sjogren\$ adj2 syndrome).tw.	9.171
6	(sicca adj2 syndrome).tw.	499
7	still\$ disease.tw.	1.369
8	bechterew\$ disease.tw.	85
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	89.891
10	Antirheumatic Agents/	19.043
11	disease modifying antirheumatic drug\$.tw.	3.004
12	(disease modifying anti-rheumatic drug\$ or DMARD\$).tw.	3.875
13	methotrexate/	17.798
14	(mexate or Abitrexate or Amet?opterine or mexate or Abitrexate or A Met?opterine or Antifolan or Emt?exate or Enthexate or Farmitrexate or Folex or Ledertrexate or Methoblastin or Methohexate or Methotrate or Methylaminopterin or Metotrexat\$ or Mtx or Novatrex or Rheumatrex or Methotrexate).tw.	24.953
15	sulfasalazine/	1.746
16	(Salazosulfapyridine or sulfasalazine or Sulfosalazine or Sulfasal#zine or Salazopyridin\$ or asulfidine or azulf#dine).tw.	2.211
17	Sulfasalazine.rn.	1.746
18	exp Isoxazoles/	9.247
19	isoxazole\$.tw.	4.346
20	isoxazole\$.tw.	4.346
21	isoxazole\$.rw.	7.621
22	le?unomide\$.tw.	6
23	le?unomide\$.rn.	0
24	hydroxychloroquine/	1.708
25	hydroxychloroquine\$.tw.	2.433
26	Cyclosporine/	21.577
27	(c*closporin* or neoral* or sandimmun*).tw.	32.197
28	Azathioprine/	5.979
29	(az?thioprine or (azathioprine adj3 sodium adj3 salt) or immur*).tw.	9.082
30	Minocycline/	4.139
31	minocycline.tw.	4.398
32	Gold/	24.085
33	gold.tw.	108.172
34	Receptors, Tumor Necrosis Factor/	13.314

35	tumor necrosis factor antibody/ or tumor necrosis factor/ or tumor necrosis factor alpha/	95.418
36	anti tumor necrosis factor alpha.tw.	1.253
37	(anti-TNF or anti TNF).tw.	7.642
38	(TNF inhibitor\$ or TNFi).tw.	1.505
39	((tumor or tumour) adj necrosis factor adj (block\$ or inhibitor\$)).tw.	1.097
40	anti-tumour necrosis factor\$.tw.	1.078
41	(Tumor Necrosis Factor-alpha adj3 inhibition).tw.	424
42	(tnf adj3 inhibition).tw.	2.184
43	Antibodies, Monoclonal/	102.366
44	(mab ca2 or monoclonal antibod\$ ca2).tw. and (dt or tu).fs.	18
45	Infliximab/	8.542
46	infliximab.tw.	9.865
47	remicade.tw.	285
48	Interferons/	8.139
49	interferon.tw.	98.780
50	Adalimumab/	3.923
51	adalimumab.tw.	4.862
52	humira.tw.	171
53	Etanercept/	5.011
54	etanercept.tw.	5.714
55	enbrel.tw.	259
56	Biological Therapy/	1.940
57	Immunologic Factors/	17.061
58	daclizumab.mp.	1.042
59	(dacliz?mab or dacl?zumab or zenapax or alemtuzumab or campath).tw.	3.189
60	Rituximab/	11.077
61	rituxan.tw.	269
62	mabthera.tw.	155
63	Golimumab.tw.	675
64	golimum\$.tw.	675
65	Certolizumab Pegol/	424
66	(CDP870 or CDP 870 or "certolizumab pegol" or certolizumab or CDP-870 or cimzia).tw.	751
67	Receptors, Interleukin-6/	2.380
68	Interleukin-6/	48.082
69	Tocilizum\$.af.	1.990
70	altizumab.af.	0
71	actemra.tw.	28
72	anti-IL-6.tw.	966
73	anti-interluekin-6.tw.	2
74	interluekin-6.tw.	19
75	Interleukin 1 Receptor Antagonist Protein/	3.981
76	anakinra.tw.	1.258
77	Auranofin/	282

78	(auranofin or crisinor or ridaur* or "sk&f 39162" or "sk&f d 39162" or "sk&f-39162" or "sk&f39162").ti,ab.	419
79	Cyclophosphamide/	22.013
80	(cyclophosph\$ or cytophosphan or cytoxan or sendoxan or endoxan or neosar or nsc-26271 or procytox or b-518 or ifosfamide or iso endoxan or isophosphamide or iphosphamide or isofosfamide or holoxan or nsc-109\$ or asta z 4942 or cfx or phosphoramid mustard\$).ti,ab.	30.816
81	Penicillamine/	2.168
82	(copper penicillamate or cuprenil or cuprimine or d 3 mercaptovaline or d penicillamine or d-3-mercaptovaline or d-penicillamine or dimethylcysteine or mercaptovaline or metalcaptase or penicillamate, copper or penicillamine or "beta,beta dimethylcysteine" or "beta,beta-dimethylcysteine").ti,ab.	2.532
83	10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82	578.005
84	9 and 83	27.984
85	Drug Therapy, Combination/	102.865
86	(adjunct\$ or adjuvant\$ or combin\$ or cotreat\$ or co-treat\$ or coadministr\$ or co-administr\$ or synerg\$ or isobol\$ or "add on\$" or polytherapy).tw.	1.415.291
87	(concomitant adj3 (anti-rheumatic\$ or antirheumatic\$ or DMARD)).tw.	59
88	((optimal or rational or DMARD or anti-rheumatic\$ or antirheumatic\$) adj3 combination\$).tw.	4.195
89	85 or 86 or 87 or 88	1.470.021
90	84 and 89	5.730
91	(letter or "case report*" or "historical article*" or (comment or editorial or in vitro or news)).pt.	2.355.322
92	90 not 91	4.937
93	meta-analysis.pt.	77.450
94	meta-analysis/ or systematic review/ or meta-analysis as topic/ or "meta analysis (topic)" or "systematic review (topic)" or exp technology assessment, biomedical/	97.569
95	((systematic* adj3 (review* or overview*)) or (methodologic* adj3 (review* or overview*))).ti,ab.	118.335
96	((quantitative adj3 (review* or overview* or synthes*)) or (research adj3 (integrati* or overview*))).ti,ab.	7.228
97	((integrative adj3 (review* or overview*)) or (collaborative adj3 (review* or overview*)) or (pool* adj3 analy*)).ti,ab.	17.542
98	(data synthes* or data extraction* or data abstraction*).ti,ab.	18.226
99	(handsearch* or hand search*).ti,ab.	7.452
100	(mantel haenszel or peto or der simonian or dersimonian or fixed effect* or latin square*).ti,ab.	18.129
101	(met analy* or metanaly* or technology assessment* or HTA or HTAs or technology overview* or technology appraisal*).ti,ab.	5.877
102	(meta regression* or metaregression*).ti,ab.	5.424
103	(meta-analy* or metaanaly* or systematic review* or biomedical technology assessment* or bio-medical technology assessment*).mp,hw.	198.946

104	(medline or cochrane or pubmed or medlars or embase or cinahl).ti,ab,hw.	148.464
105	(cochrane or (health adj2 technology assessment) or evidence report).jw.	16.513
106	(meta-analysis or systematic review).tw.	157.357
107	(comparative adj3 (efficacy or effectiveness)).ti,ab.	8.164
108	(outcomes research or relative effectiveness).ti,ab.	5.115
109	((indirect or indirect treatment or mixed-treatment) adj comparison*).ti,ab.	1.481
110	93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109	316.992
111	92 and 110	363
112	animals/ not (animals/ and humans/)	2.154.062
113	111 not 112	360
114	limit 113 to (english or spanish)	346

Tabla 2. Estrategia de búsqueda para ensayos clínicos aleatorizados en Medline.

#	Términos de la búsqueda	Citas
1	exp arthritis, rheumatoid/	52.723
2	((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat\$ or reumat\$ or revmarthrit\$) adj3 (arthrit\$ or artrit\$ or diseas\$ or condition\$ or nodule\$)).tw.	73.409
3	(felty\$ adj2 syndrome).tw.	177
4	(caplan\$ adj2 syndrome).tw.	20
5	(sjogren\$ adj2 syndrome).tw.	9.185
6	(sicca adj2 syndrome).tw.	499
7	still\$ disease.tw.	1.371
8	bechterew\$ disease.tw.	85
9	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	89.996
10	Antirheumatic Agents/	19.047
11	disease modifying antirheumatic drug\$.tw.	3.010
12	(disease modifying anti-rheumatic drug\$ or DMARD\$).tw.	3.883
13	methotrexate/	17.802
14	(mexate or Abitrexate or Amet?opterine or mexate or Abitrexate or A Met?opterine or Antifolan or Emt?exate or Enthexate or Farnitrexate or Folex or Ledertrexate or Methoblastin or Methohexate or Methotrate or Methylaminopterin or Metotrexat\$ or Mtx or Novatrex or Rheumatrex or Methotrexate).tw.	24.975
15	sulfasalazine/	1.746
16	(Salazosulfapyridine or sulfasalazine or Sulfosalazine or Sulfasal#zine or Salazopyridin\$ or asulfidine or azulf#dine).tw.	2.216
17	Sulfasalazine.rn.	1.746
18	exp Isoxazoles/	9.257
19	isoxazole\$.tw.	4.356
20	isoxazole\$.tw.	4.356
21	isoxazole\$.rw.	7.627
22	le?unomide\$.tw.	6

23	le?unomide\$.rn.	0
24	hydroxychloroquine/	1.710
25	hydroxychloroquine\$.tw.	2.435
26	Cyclosporine/	21.578
27	(c*closporin* or neoral* or sandimmun*).tw.	32.204
28	Azathioprine/	5.983
29	(az?thioprine or (azathioprine adj3 sodium adj3 salt) or immur*).tw.	9.090
30	Minocycline/	4.146
31	minocycline.tw.	4.406
32	Gold/	24.097
33	gold.tw.	108.296
34	Receptors, Tumor Necrosis Factor/	13.314
35	tumor necrosis factor antibody/ or tumor necrosis factor/ or tumor necrosis factor alpha/	95.484
36	anti tumor necrosis factor alpha.tw.	1.253
37	(anti-TNF or anti TNF).tw.	7.651
38	(TNF inhibitor\$ or TNFi).tw.	1.507
39	((tumor or tumour) adj necrosis factor adj (block\$ or inhibitor\$)).tw.	1.099
40	anti-tumour necrosis factor\$.tw.	1.078
41	(Tumor Necrosis Factor-alpha adj3 inhibition).tw.	424
42	(tnf adj3 inhibition).tw.	2.186
43	Antibodies, Monoclonal/	102.414
44	(mab ca2 or monoclonal antibod\$ ca2).tw. and (dt or tu).fs.	18
45	Infliximab/	8.545
46	infliximab.tw.	9.870
47	remicade.tw.	285
48	Interferons/	8.146
49	interferon.tw.	98.902
50	Adalimumab/	3.928
51	adalimumab.tw.	4.870
52	humira.tw.	171
53	Etanercept/	5.012
54	etanercept.tw.	5.720
55	enbrel.tw.	259
56	Biological Therapy/	1.941
57	Immunologic Factors/	17.070
58	daclizumab.mp.	1.042
59	(dacliz?mab or dacl?zumab or zenapax or alemtuzumab or campath).tw.	3.191
60	Rituximab/	11.082
61	rituxan.tw.	269
62	mabthera.tw.	155
63	Golimumab.tw.	678
64	golimum\$.tw.	678
65	Certolizumab Pegol/	425

66	(CDP870 or CDP 870 or "certolizumab pegol" or certolizumab or CDP-870 or cimzia).tw.	753
67	Receptors, Interleukin-6/	2.380
68	Interleukin-6/	48.129
69	Tocilizum\$.af.	1.996
70	altizumab.af.	0
71	actemra.tw.	28
72	anti-IL-6.tw.	967
73	anti-interluekin-6.tw.	2
74	interluekin-6.tw.	19
75	Interleukin 1 Receptor Antagonist Protein/	3.983
76	anakinra.tw.	1.259
77	Auranofin/	282
78	(auranofin or crisinor or ridaur* or "sk&f 39162" or "sk&f d 39162" or "sk&f-39162" or "sk&f39162").ti,ab.	419
79	Cyclophosphamide/	22.018
80	(cyclophosph\$ or cytophosphan or cytoxan or sendoxan or endoxan or neosar or nsc-26271 or procytox or b-518 or ifosfamide or iso endoxan or isophosphamide or iphosphamide or isofosfamide or holoxan or nsc-109\$ or asta z 4942 or cfx or phosphoramidate mustard\$).ti,ab.	30.836
81	Penicillamine/	2.168
82	(copper penicillamate or cuprenil or cuprimine or d 3 mercaptovaline or d penicillamine or d-3-mercaptovaline or d-penicillamine or dimethylcysteine or mercaptovaline or metalcaptase or penicillamate, copper or penicillamine or "beta,beta dimethylcysteine" or "beta,beta-dimethylcysteine").ti,ab.	2.532
83	10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82	578.515
84	9 and 83	28.006
85	Drug Therapy, Combination/	102.923
86	(adjunct\$ or adjuvant\$ or combin\$ or cotreat\$ or co-treat\$ or coadministr\$ or co-administr\$ or synerg\$ or isobol\$ or "add on\$" or polytherapy).tw.	1.417.407
87	(concomitant adj3 (anti-rheumatic\$ or antirheumatic\$ or DMARD)).tw.	59
88	((optimal or rational or DMARD or anti-rheumatic\$ or antirheumatic\$) adj3 combination\$).tw.	4.207
89	85 or 86 or 87 or 88	1.472.164
90	84 and 89	5.734
91	(letter or "case report*" or "historical article*" or (comment or editorial or in vitro or news)).pt.	2.356.965
92	90 not 91	4.941
93	Randomized Controlled Trials as Topic/	103.308
94	Randomized controlled trial/	348.157
95	Random Allocation/	57.193
96	Double Blind Method/	96.860
97	Single Blind Method/	21.369

98	Clinical trial/	306.058
99	Clinical trial, phase i.pt.	15.491
100	Clinical trial, phase ii.pt.	25.446
101	Clinical trial, phase iii.pt.	12.095
102	Clinical trial, phase iv.pt.	1.335
103	Controlled clinical trial.pt.	46.514
104	Randomized controlled trial.pt.	348.157
105	Multicenter study.pt.	203.253
106	Multicenter study.pt.	203.253
107	Clinical trial.pt.	306.058
108	(clinical adj trial\$).tw.	256.182
109	((singl\$ or doubl\$ o rtreb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw.	12.819
110	placebos/	15.548
111	placebo\$.tw.	144.210
112	Randomly allocated.tw.	19.006
113	(allocated adj2 random\$).tw.	20.874
114	93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113	1.069.323
115	case report.tw.	191.129
116	letter/	658.704
117	Historical article/	153.905
118	115 or 116 or 117	992.792
119	114 not 118	1.048.976
120	114 not 118	1.048.976
121	(letter or "case report*" or "historical article*" or (comment or editorial or in vitro or news)).pt.	23.56.965
122	120 not 121	1.028.768
123	92 and 122	1.858
124	animals/ not (animals/ and humans/)	2.155.632
125	123 not 124	1.838
126	limit 125 to (english or spanish)	1.692

Tabla 3. Estrategia de búsqueda para revisiones sistemáticas y meta-análisis en Embase.

#	Términos de la búsqueda	Citas
105	#104 AND [embase]/lim NOT [medline]/lim AND ([english]/lim OR [spanish]/lim)	64
104	#74 AND #103	332
103	#102 NOT #101	222.183
102	#75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89 OR #94	183.680
101	#95 OR #96 OR #100	4.682.964
100	#97 NOT #99	4.682.964
99	#97 AND #98	17.194.574
98	'human'/exp	17.194.574
97	'animal'/exp	21.877.538

96	editorial:pt	0
95	letter:pt	0
94	#92 AND #93	0
93	'review':pt	0
92	#90 OR #91	38.569
91	'selection criteria':ab	24.946
90	'data extraction':ab	15.121
89	'relevant journals':ab	1.017
88	'manual search?'	1
87	'hand search?'	0
86	bibliograph?	10.942
85	'reference lists':ab	12.731
84	bids.ab	0
83	cinahl:ab OR cinhal:ab	16.543
82	psychinfo:ab OR psycinfo:ab	13.293
81	psychlit:ab OR psyclit:ab	957
80	embase:ab	54.605
79	'cochrane':ab	54.291
78	cancerlit:ab	672
77	(systematic NEAR/1 (review? OR overvie?)):ab,ti	17.335
76	(meta NEAR/3 analy?) OR metaanalys?	433
75	'meta analysis'/exp	109.436
74	#72 NOT #73	8.601
73	'conference abstract'/it OR 'conference paper'/it OR 'note'/it OR 'short survey'/it	4.467.898
72	#66 AND #71	12.621
71	#67 OR #68 OR #69 OR #70	2.443.701
70	((optimal OR rational OR dmard OR 'anti rheumatic*' OR antirheumatic*) NEAR/3 combination*):ti,ab	6.416
69	(concomitant NEAR/3 ('anti rheumatic*' OR antirheumatic* OR dmard)):ti,ab	214
68	adjunct*:ti,ab OR adjuvant*:ti,ab OR combin*:ti,ab OR cotreat*:ti,ab OR 'co treat*':ti,ab OR coadministr*:ti,ab OR 'co administr*':ti,ab OR synerg*:ti,ab OR isobol*:ti,ab OR 'add on*':ti,ab OR polytherapy:ti,ab	2.351.516
67	'combination drug therapy'/exp	154.345
66	#9 AND #65	89.204
65	#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62OR #63 OR #64	2.217.519
64	('copper penicillamine':ti,ab OR cuprenil:ti,ab OR cuprimine:ti,ab OR 'd 3 mercaptovaline':ti,ab OR 'd penicillamine':ti,ab OR 'd-3-mercaptovaline':ti,ab OR 'd-penicillamine':ti,ab OR dimethylcysteine:ti,ab OR mercaptovaline:ti,ab OR metalcaptase:ti,ab OR penicillamine:,ti,ab) AND copper:ti,ab OR penicillamine:ti,ab OR 'beta,beta dimethylcysteine':ti,ab OR 'beta,beta-dimethylcysteine':ti,ab	8.698
63	'penicillamine'/exp	18.248

62	((((cyclophosph*:ti,ab OR cytophosphan:ti,ab OR cytoxan:ti,ab OR sendoxan:ti,ab OR endoxan:ti,ab OR neosar:ti,ab OR 'nsc 26271':ti,ab OR procytox:ti,ab OR 'b 518':ti,ab OR ifosfamide:ti,ab OR iso:ti,ab) AND endoxan:ti,ab OR isophosphamide:ti,ab OR iphosphamide:ti,ab OR isofosfamide:ti,ab OR holoxan:ti,ab OR 'nsc 109*':ti,ab OR asta:ti,ab) AND z:ti,ab AND 4942:ti,ab OR cfx:ti,ab OR phosphoramidate:ti,ab) AND mustard*:ti,ab	368
61	'cyclophosphamide'/exp	196.697
60	auranofin:ti,ab OR crisinor:ti,ab OR ridaur*:ti,ab OR 'sk&f 39162':ti,ab OR 'sk&f d 39162':ti,ab OR 'sk&f-39162':ti,ab OR 'sk&f39162':ti,ab	1.210
59	'auranofin'/exp	2.745
58	anakinra:ab,ti	2.405
57	'interleukin 1 receptor blocking agent'/exp/mj	2.673
56	'interluekin 6'	46
55	'anti il 6':ab,ti OR 'anti-interluekin-6':ab,ti OR 'interluekin-6':ab,ti	1.895
54	altizumab:ab,ti OR actemra:ab,ti	52
53	'tocilizumab'/exp OR tocilizum\$:ab,ti	7.396
52	'interleukin 6'/exp/mj	30.769
51	'interleukin 6 receptor'/exp	4.364
50	(cdp870:ab,ti OR cdp:ab,ti) AND 870:ab,ti OR 'certolizumab pegol':ab,ti OR certolizumab:ab,ti OR 'cdp 870':ab,ti OR cimzia:ab,ti	2.158
49	'certolizumab pegol'/exp	4.506
48	'golimumab'/exp OR golimum\$:ab,ti	4.337
47	'rituximab'/exp OR rituxan:ab,ti OR mabthera:ab,ti	59.970
46	'daclizumab'/exp OR dacliz?mab OR dacl?zumab OR zenapax OR alemtuzumab OR campath	17.795
45	'biological therapy'/exp/mj	588.837
44	'etanercept'/exp OR etanercept:ab,ti OR enbrel:ab,ti	26.147
43	'adalimumab'/exp OR adalimumab:ab,ti OR humira:ab,ti	24.459
42	'interferon'/exp/mj OR interferon:ab,ti	221.146
41	'infliximab'/exp OR infliximab:ab,ti OR remicade:ab,ti	40.639
40	'mab ca2 or monoclonal antibod\$ ca2':ab,ti	0
39	'monoclonal antibody'/exp	450.412
38	(tnf NEAR/3 inhibition):ab,ti	3.142
37	('tumor necrosis factor' NEAR/3 inhibition):ab,ti	747
36	'anti-tumour necrosis factor\$:ab,ti	1.534
35	(tumor:ab,ti OR tumour:ab,ti) AND necrosis:ab,ti AND factor:ab,ti AND near:ab,ti AND (block\$:ab,ti OR inhibitor\$:ab,ti)	161
34	'tnf inhibitor\$:ab,ti OR tnfi:ab,ti	3.701
33	'anti-tnf':ab,ti OR 'anti tnf':ab,ti	16.813
32	'tumor necrosis factor alpha'/exp OR 'tumor necrosis factor'/exp	242.792
31	'tumor necrosis factor antibody'/exp	9.823
30	'tumor necrosis factor receptor'/exp	10.472
29	gold:ab,ti	158.017
28	'gold'/exp	44.235
27	minocycline:ab,ti	7.769
26	'minocycline'/exp	21.086

25	az?thioprine OR (azathioprine NEAR/3 sodium NEAR/3 salt) OR immur*	87.463
24	'cyclosporin'/exp	74.486
23	cyclosporin*:ab,ti OR neoral*:ab,ti OR sandimmun*:ab,ti	61.913
22	hydroxychloroquine\$:ab,ti	5.388
21	'hydroxychloroquine'/exp	18.939
20	le?unomide\$	13
19	isoxazole\$:ab,ti	3.557
18	'isoxazole derivative'/exp	39.207
17	sulfasalazine:tn	45
16	salazosulfapyridine OR sulfasalazine OR sulfosalazine OR sulfasal?zine OR salazopyridin\$ OR asulfidine OR azulf?dine	23.088
15	'salazosulfapyridine'/exp	22.597
14	(amet?opterine OR mexate OR abitrexate OR 'a met?opterine' OR antifolan OR emt?exate OR enthexate OR farmitrexate OR folexOR ledertrexate OR methoblastin OR methohexate OR methotrate OR methylaminopterin OR metotrexat\$ OR mtx OR novatrexor) AND rheumatrex OR methotrexate	162.464
13	'methotrexate'/exp	157.913
12	'disease modifying anti-rheumatic drug\$:ab,ti OR dmard\$:ab,ti	10.745
11	'disease modifying antirheumatic drug\$:ab,ti	4.490
10	'antirheumatic agent'/exp	534.539
9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	249.548
8	'bechterew* disease':ti,ab	82
7	'still* disease':ti,ab	452
6	(sicca NEXT/2 syndrome):ti,ab	1.029
5	(sjogren* NEXT/2 syndrome):ti,ab	16.795
4	(caplan* NEXT/2 syndrome):ti,ab	212
3	(felty* NEXT/2 syndrome):ti,ab	918
2	((rheumatoid OR reumatoid OR revmatoid OR rheumatic OR reumatic OR revmatic OR rheumat* OR reumat* OR revmarthrit*) NEXT/3 (arthrit* OR artrit* OR disea* OR condition* OR nodule*)):ti,ab	164.159
1	'rheumatoid arthritis'/exp	184.853

Tabla 4. Estrategia de búsqueda para ensayos clínicos aleatorizados en Embase.

#	Términos de la búsqueda	Citas
95	#94 AND [embase]/lim NOT [medline]/lim AND ([english]/lim OR [spanish]/lim)	473
94	#74 AND #93	2.655
93	#88 NOT #92	1.778.817
92	#89 OR #90 OR #91	1.387.759
91	'abstract report'/exp OR 'letter'/exp	999.471
90	'case report':ab,ti	342.784
89	'case study'/exp	52.979
88	#75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87	1.695.512
87	'prospective study'/exp	352.138
86	placebo?	3.076

85	((treble OR triple) NEAR/1 blind?):ab,ti	0
84	'double blind?'	15
83	'single blind?'	0
82	(allocated NEAR/2 random):ab,ti	925
81	'randomly allocated':ab,ti	26.304
80	'random allocation':ab,ti	1.653
79	random AND allocation:ab,ti	3.420
78	rct:ab,ti	22.711
77	'randomi?ed controlled trial?'	70.964
76	'clinical trial'/exp OR 'randomized controlled trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp	1.377.437
75	'clinical trial'/exp	1.154.476
74	#72 NOT #73	8.601
73	'conference abstract'/it OR 'conference paper'/it OR 'note'/it OR 'short survey'/it	4.467.898
72	#66 AND #71	12.621
71	#67 OR #68 OR #69 OR #70	2.443.701
70	((optimal OR rational OR dmard OR 'anti rheumatic*' OR antirheumatic*) NEAR/3 combination*):ti,ab	6.416
69	(concomitant NEAR/3 ('anti rheumatic*' OR antirheumatic* OR dmard)):ti,ab	214
68	adjunct*:ti,ab OR adjuvant*:ti,ab OR combin*:ti,ab OR cotreat*:ti,ab OR 'co treat*:ti,ab OR coadministr*:ti,ab OR 'co administr*:ti,ab OR synerg*:ti,ab OR isobol*:ti,ab OR 'add on*:ti,ab OR polytherapy:ti,ab	2.351.516
67	'combination drug therapy'/exp	154.345
66	#9 AND #65	89.204
65	#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64	2.217.519
64	('copper penicillamate':ti,ab OR cuprenil:ti,ab OR cuprimine:ti,ab OR 'd 3 mercaptovaline':ti,ab OR 'd penicillamine':ti,ab OR 'd-3-mercaptovaline':ti,ab OR 'd-penicillamine':ti,ab OR dimethylcysteine:ti,ab OR mercaptovaline:ti,ab OR metalcaptase:ti,ab OR penicillamate:,ti,ab) AND copper:ti,ab OR penicillamine:ti,ab OR 'beta,beta dimethylcysteine':ti,ab OR 'beta,beta-dimethylcysteine':ti,ab	8.698
63	'penicillamine'/exp	18.248
62	((((cyclophosph*:ti,ab OR cytophosphan:ti,ab OR cytoxan:ti,ab OR sendoxan:ti,ab OR endoxan:ti,ab OR neosar:ti,ab OR 'nsc 26271':ti,ab OR procytox:ti,ab OR 'b 518':ti,ab OR ifosfamide:ti,ab OR iso:ti,ab) AND endoxan:ti,ab OR isophosphamide:ti,ab OR iphosphamide:ti,ab OR isofosfamide:ti,ab OR holoxan:ti,ab OR 'nsc 109*':ti,ab OR asta:ti,ab) AND z:ti,ab AND 4942:ti,ab OR cfx:ti,ab OR phosphoramidate:ti,ab) AND mustard*:ti,ab	368
61	'cyclophosphamide'/exp	196.697
60	auranofin:ti,ab OR crisinor:ti,ab OR ridaur*:ti,ab OR 'sk&f 39162':ti,ab OR 'sk&f d 39162':ti,ab OR 'sk&f-39162':ti,ab OR 'sk&f39162':ti,ab	1.210
59	'auranofin'/exp	2.745
58	anakinra:ab,ti	2.405

57	'interleukin 1 receptor blocking agent'/exp/mj	2.673
56	'interluekin 6'	46
55	'anti il 6':ab,ti OR 'anti-interluekin-6':ab,ti OR 'interluekin-6':ab,ti	1.895
54	altizumab:ab,ti OR actemra:ab,ti	52
53	'tocilizumab'/exp OR tocilizum\$:ab,ti	7.396
52	'interleukin 6'/exp/mj	30.769
51	'interleukin 6 receptor'/exp	4.364
50	(cdp870:ab,ti OR cdp:ab,ti) AND 870:ab,ti OR 'certolizumab pegol':ab,ti OR certolizumab:ab,ti OR 'cdp 870':ab,ti OR cimzia:ab,ti	2.158
49	'certolizumab pegol'/exp	4.506
48	'golimumab'/exp OR golimum\$:ab,ti	4.337
47	'rituximab'/exp OR rituxan:ab,ti OR mabthera:ab,ti	59.970
46	'daclizumab'/exp OR dacliz?mab OR dacl?zumab OR zenapax OR alemtuzumab OR campath	17.795
45	'biological therapy'/exp/mj	588.837
44	'etanercept'/exp OR etanercept:ab,ti OR enbrel:ab,ti	26.147
43	'adalimumab'/exp OR adalimumab:ab,ti OR humira:ab,ti	24.459
42	'interferon'/exp/mj OR interferon:ab,ti	221.146
41	'infliximab'/exp OR infliximab:ab,ti OR remicade:ab,ti	40.639
40	'mab ca2 or monoclonal antibod\$ ca2':ab,ti	0
39	'monoclonal antibody'/exp	450.412
38	(tnf NEAR/3 inhibition):ab,ti	3.142
37	('tumor necrosis factor' NEAR/3 inhibition):ab,ti	747
36	'anti-tumour necrosis factor\$:ab,ti	1.534
35	(tumor:ab,ti OR tumour:ab,ti) AND necrosis:ab,ti AND factor:ab,ti AND near:ab,ti AND (block\$:ab,ti OR inhibitor\$:ab,ti)	161
34	'tnf inhibitor\$:ab,ti OR tnfi:ab,ti	3.701
33	'anti-tnf':ab,ti OR 'anti tnf':ab,ti	16.813
32	'tumor necrosis factor alpha'/exp OR 'tumor necrosis factor'/exp	242.792
31	'tumor necrosis factor antibody'/exp	9.823
30	'tumor necrosis factor receptor'/exp	10.472
29	gold:ab,ti	158.017
28	'gold'/exp	44.235
27	minocycline:ab,ti	7.769
26	'minocycline'/exp	21.086
25	az?thioprine OR (azathioprine NEAR/3 sodium NEAR/3 salt) OR immur*	87.463
24	'cyclosporin'/exp	74.486
23	cyclosporin*:ab,ti OR neoral*:ab,ti OR sandimmun*:ab,ti	61.913
22	hydroxychloroquine\$:ab,ti	5.388
21	'hydroxychloroquine'/exp	18.939
20	le?unomide\$	13
19	isoxazole\$:ab,ti	3.557
18	'isoxazole derivative'/exp	39.207
17	sulfasalazine:tn	45

16	salazosulfapyridine OR sulfasalazine OR sulfosalazine OR sulfasalazine OR salazopyridin\$ OR asulfidine OR azulfidine	23.088
15	'salazosulfapyridine'/exp	22.597
14	(amet?opterine OR mexate OR abitrexate OR 'a met?opterine' OR antifolan OR emt?exate OR enthexate OR farmitrexate OR folex OR ledertrexate OR methoblastin OR ethohexate OR methotrate OR methylaminopterin OR metotrexat\$ OR mtx OR novatrex) AND rheumatrex OR methotrexate	162.464
13	'methotrexate'/exp	157.913
12	'disease modifying anti-rheumatic drug\$:ab,ti OR dmard\$:ab,ti	10.745
11	'disease modifying antirheumatic drug\$:ab,ti	4.490
10	'antirheumatic agent'/exp	534.539
9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	249.548
8	'bechterew* disease':ti,ab	82
7	'still* disease':ti,ab	452
6	(sicca NEXT/2 syndrome):ti,ab	1.029
5	(sjogren* NEXT/2 syndrome):ti,ab	16.795
4	(caplan* NEXT/2 syndrome):ti,ab	212
3	(felty* NEXT/2 syndrome):ti,ab	918
2	((rheumatoid OR reumatoid OR revmatoid OR rheumatic OR reumatic OR revmatic OR rheumat* OR reumat* OR revmarthrit*) NEXT/3 (arthrit* OR artrit* OR disea* OR condition* OR nodule*)):ti,ab	164.159
1	'rheumatoid arthritis'/exp	184.853

Tabla 5. Estrategia de búsqueda para la Cochrane Library.

#	Términos de la búsqueda	Citas
1	[mh "arthritis rheumatoid"]	4.747
2	((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat* or reumat* or revmarthrit*) next/3 (arthrit* or artrit* or disea* or condition* or nodule*)):ti,ab	9.304
3	(felty* next/2 syndrome):ti,ab	2
4	(caplan* next/2 syndrome):ti,ab	0
5	(sjogren* next/2 syndrome):ti,ab	415
6	(sicca next/2 syndrome):ti,ab	28
7	'still* disease':ti,ab	6.517
8	'bechterew* disease':ti,ab	31
9	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8	16.432
10	MeSH descriptor: [Antirheumatic Agents] this term only	2.042
11	"disease modifying antirheumatic drug":ti,ab,kw (Word variations have been searched)	918
12	MeSH descriptor: [Methotrexate] explode all trees	216
13	(amet?opterine or mexate or abitrexate or 'a met?opterine' or antifolan or emt?exate or enthexate or farmitrexate or folex or ledertrexate or methoblastin or methohexate or methotrate or methylaminopterin or metotrexat\$ or mtx or novatrex or rheumatrex or methotrexate):ti,ab	6.176
14	MeSH descriptor: [Sulfasalazine] explode all trees	426

15	(salazosulfapyridine or sulfasalazine or sulfosalazine or sulfasalazine or salazopyridin* or asulfidine or azulfidine):ti,ab	5 06
16	MeSH descriptor: [Isoxazoles] explode all trees	794
17	"leflunomide" or leflunomide:ti,ab,kw (Word variations have been searched)	363
18	MeSH descriptor: [Hydroxychloroquine] explode all trees	9
19	MeSH descriptor: [Cyclosporine] this term only	2. 337
20	MeSH descriptor: [Azathioprine] explode all trees	1.127
21	azathioprine or azathioprine near/3 sodium near/3 salt or immur*:ti,ab,kw (Word variations have been searched)	2.732
22	MeSH descriptor: [Minocycline] explode all trees	330
23	MeSH descriptor: [Gold] explode all trees	140
24	MeSH descriptor: [Receptors, Tumor Necrosis Factor] this term only	677
25	MeSH descriptor: [Tumor Necrosis Factor-alpha] this term only	2.989
26	'anti-tnf' or 'anti tnf':ti,ab,kw (Word variations have been searched)	2.123
27	"anti-tumour necrosis factor*":ti,ab,kw (Word variations have been searched)	441
28	('tumor necrosis factor-alpha' near/3 inhibition)	10
29	('tumor necrosis factor-alpha' near/3 inhibition):ti,ab,kw (Word variations have been searched)	7
30	(tnf near/3 inhibition):ti,ab,kw (Word variations have been searched)	56
31	MeSH descriptor: [Antibodies, Monoclonal] this term only	4.612
32	'mab ca2 or monoclonal antibody ca2':ti,ab,kw (Word variations have been searched)	2
33	MeSH descriptor: [Infliximab] explode all trees	479
34	MeSH descriptor: [Interferons] this term only	398
35	MeSH descriptor: [Adalimumab] explode all trees	308
36	adalimumab or humira:ti,ab,kw (Word variations have been searched)	1.435
37	MeSH descriptor: [Etanercept] explode all trees	426
38	etanercept or enbrel:ti,ab,kw (Word variations have been searched)	1.309
39	MeSH descriptor: [Biological Therapy] this term only	61
40	daclizumab:ti,ab,kw (Word variations have been searched)	427
41	daclizumab or daclizumab or zenapax or alemtuzumab or campath:ti,ab,kw (Word variations have been searched)	855
42	MeSH descriptor: [Rituximab] explode all trees	446
43	golimumab:ti,ab,kw (Word variations have been searched)	362
44	MeSH descriptor: [Certolizumab Pegol] explode all trees	74
45	cdp870 or "cdp 870" or 'certolizumab pegol' or certolizumab or 'cdp 870' or cimzia:ti,ab,kw (Word variations have been searched)	320
46	MeSH descriptor: [Receptors, Interleukin-6] explode all trees	72
47	MeSH descriptor: [Interleukin-6] this term only	2.675
48	tocilizumab:ti,ab,kw (Word variations have been searched)	436
49	altizumab or actemra:ti,ab,kw (Word variations have been searched)	6
50	'anti il 6' or 'anti-interleukin-6' or 'interleukin-6':ti,ab,kw (Word variations have been searched)	2.004
51	MeSH descriptor: [Interleukin 1 Receptor Antagonist Protein] explode all trees	208
52	anakinra:ti,ab	133

53	[mh Auranofin]	9 2
54	(auranofin or crisinor or ridaur* or "sk&f 39162" or "sk&f d 39162" or "sk&f-39162" or "sk&f39162"):ti,ab	140
55	[mh Cyclophosphamide]	4.179
56	(cyclophosph* or cytophosphan or cytoxan or sendoxan or endoxan or neosar or nsc-26271 or procytox or b-518 or ifosfamide or iso endoxan or isophosphamide or iphosphamide or isofosfamide or holoxan or nsc-109* or asta z 4942 or cfx or phosphoramidate mustard*):ti,ab	7.687
57	#10 or #11 or #12 or #13 or #14 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56	32.809
58	#9 and #57	4.661
59	[mh ^"Drug Therapy Combination"]	28.857
60	(adjunct* or adjuvan* or combin* or cotreat or co-treat* or coadministr* or co-administr* or synerg* or isobol* or "add o*" or polytherapy):ti	5 6.569
61	(concomitant near/3 (anti-rheumatic* or antirheumatic* or DMARD)):ti,ab	3 2
62	((optimal or rational or DMARD or anti-rheumatic* or antirheumatic*) near/3 combination*):ti,ab	330
63	#59 or #60 or #61 or #62	77.769
64	#58 and #63 in Trials	1.025

Tabla 6. Estudios excluidos y motivos de exclusión.

#	Estudio	Motivos de exclusión
1	Akdemir_2016 (1)	No contesta ninguna pregunta de la RSL
2	Allaart_2006 (2)	No contesta ninguna pregunta de la RSL
3	Bakker_2010 (3)	No contesta ninguna pregunta de la RSL
4	Boers_1997 (4)	Falta brazo secuencial
5	Boers_2013 (5)	Meta-análisis cuyos ECA ya están incluidos en la presente RSL
6	Calgüneri_1999 (6)	Falta brazo secuencial
7	Capell_2007 (7)	No contesta ninguna pregunta de la RSL
8	Chatzidionysiou_2017 (8)	RSL cuyos ECA ya están incluidos en la presente revisión
9	Choy_2008 (9)	Falta el brazo terapia combinada, brazos de tratamiento no claros
10	Daien_2017(10)	RSL cuyos ECA ya están incluidos en la presente revisión
11	de Jong_2013 (11)	Triple terapia pero en pacientes con AR precoz
12	de Jong_2014 (12)	Triple terapia pero en pacientes con AR precoz
13	Dirven_2012 (13)	No contesta ninguna pregunta de la RSL
14	Dougados_1999 (14)	Falta brazo secuencial
15	Ferraz_1994 (15)	No contesta ninguna pregunta de la RSL
16	Fleischmann_2014 (16)	No contesta ninguna pregunta de la RSL
17	Gaujoux-Viala_2014 (17)	RSL cuyos ECA ya están incluidos en la presente revisión
18	Gerards_2003 (18)	Falta brazo secuencial y son AR de < 3 años de evolución

19	Goekoop-Ruiterman_2005 (19)	No contesta ninguna pregunta de la RSL
20	Goekoop-Ruiterman_2007 (20)	No contesta ninguna pregunta de la RSL
21	Ghosh_2008 (21)	Falta brazo secuencial
22	Giacomelli_2002 (22)	Falta brazo secuencial
23	Gibson_1987 (23)	Falta brazo secuencial y duración AR no clara
24	Grigor_2004 (24)	Triple terapia (2 diferentes) pero difícil extraer resultados exactos
25	Güler-Yuksele_2008 (25)	No contesta ninguna pregunta de la RSL
26	Güler-Yuksele_2009 (26)	No contesta ninguna pregunta de la RSL
27	Haagsma_1994 (27)	No contesta ninguna pregunta de la RSL
28	Haagsma_1997 (28)	Falta brazo secuencial
29	Hazlewood_2016 (29)	RSL cuyos ECA ya están incluidos en la presente revisión
30	Heimans_2013_1 (30)	No contesta ninguna pregunta de la RSL
31	Heimans_2013-2 (31)	No contesta ninguna pregunta de la RSL
32	Heimans_2016 (32)	No contesta ninguna pregunta de la RSL
33	Hetland_2006 (33)	Falta brazo secuencial
34	Karstila_2010 (34)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
35	Kauppi_2009 (35)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
36	Kim_2000 (36)	No se analiza la respuesta a combinación de FAME (iniciados simultáneamente). Pacientes con respuesta inadecuada a MTX que se aleatorizan a tratamiento combinado MTX + CsA o mantenimiento del MTX con adición de placebo
37	Klarenbeek_2011 (37)	No contesta ninguna pregunta de la RSL
38	Korpela_2004 (38)	Triple terapia en AR de inicio
39	Kremer_2002 (39)	No contesta ninguna pregunta de la RSL
40	Landewe_2002 (40)	Falta brazo secuencial
41	Lehman_2005 (41)	El brazo de combinación no es MTX+LEF
42	Leirisalo-Repo_2013 (42)	Analiza en AR de inicio el añadir IFX a la triple terapia
43	Li_2016 (43)	Son pacientes con AR que han respondido a triple terapia
44	Machein_2002 (44)	No contesta ninguna pregunta de la RSL
45	Mäkinen_2007 (45)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
46	Marchesoni_2003 (46)	Falta brazo secuencial
47	Markusse_2015 (47)	No contesta ninguna pregunta de la RSL
48	Mary_2017 (48)	RSL cuyos ECA ya están incluidos en la presente revisión
49	Mian_2016 (49)	No contesta ninguna pregunta de la RSL
50	Moreland_2012 (50)	No contesta ninguna pregunta de la RSL
51	Mottaghi_2005 (51)	Falta brazo secuencial
52	Möttönen_1999 (52)	AR precoz con triple terapia
53	Neva_2000 (53)	AR precoz aleatorizados a triple terapia o monoterapia
54	O'Dell_1996 (54)	No contesta ninguna pregunta de la RSL
55	O'Dell_2002 (55)	Hay pacientes nive a FAME
56	O'Dell_2013 (56)	No contesta ninguna pregunta de la RSL
57	Peper_2017 (57)	No contesta ninguna pregunta de la RSL
58	Puolakka_2004 (58)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)

59	Puolakka_2005 (59)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
60	Proudman_2000 (60)	Falta brazo secuencial
61	Rantalaiho_2009 (61)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
62	Rantalaiho_2010 (62)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
63	Rantalaiho_2013 (63)	Estudio FIN-RACo (AR precoz con triple terapia vs distintos ttos)
64	Rantalaiho_2014 (64)	Analiza en AR de inicio el añadir IFX a la triple terapia
65	Rau_1998 (65)	Estudio observacional
66	Sarzi-Puttini_2005 (66)	Falta brazo secuencial
67	Scott_1989 (67)	Falta brazo secuencial
68	Scott_2015 (68)	No especifica ni sub-analiza las combinaciones de nuestra RSL
69	Seegobin_2014 (69)	Falta brazo secuencial
70	Shashikumar_2010 (70)	En el estudio no se especifica el tipo de paciente con AR (inicio vs establecida) tampoco si han recibido antes del estudio FAME u otros fármacos. No hay además brazo comparativo de terapia secuencial
71	Taggart_1987 (71)	Falta brazo secuencial
72	Tugwell_1995 (72)	Análisis de la terapia combinada de MTX + CsA. No se utiliza ni una triple terapia, ni la combinación MTX + LFN
73	Van den Broek_2012 (73)	No contesta ninguna pregunta de la RSL
74	van der Goes_2013 (74)	No se evalúa una terapia combinada de FAME, ni secuencial
75	van der Kooij_2007 (75)	No Existe ningún brazo con terapia combinada de inicio
76	Van der Kooij_2009 (76)	No contesta ninguna pregunta de la RSL
77	van Vollenhoven_2009 (77)	No contesta ninguna pregunta de la RSL
78	van Vollenhoven_2012 (78)	No contesta ninguna pregunta de la RSL
79	Verstappen_2007 (79)	No contesta ninguna pregunta de la RSL
80	Verstappen_2010 (80)	No contesta ninguna pregunta de la RSL
81	Verschueren_2015 (81)	Falta brazo secuencial
82	Verschueren_2017 (82)	Falta brazo secuencial
83	Weinblatt_1999 (83)	Estudio observacional
84	Wijesinghe_2017 (84)	No contesta ninguna pregunta de la RSL
85	Willkens_1992 (85)	El brazo de combinación no es MTX+LEF
86	Willkens_1995 (86)	El brazo de combinación no es MTX+LEF

Abreviaturas: RSL=revisión sistemática de la literatura; ECA=ensayo clínico aleatorizado; AR=artritis reumatoide; MTX=metrotexato; LEF=leflunomida; CsA=ciclosporina A; IFX=infliximab; FAME=fármacos modificadores de la enfermedad.

REFERENCIAS

1. Akdemir G, Markusse IM, Dirven L, Riyazi N, Steup-Beekman GM, Kerstens P, et al. Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial. *RMD Open*. 2016;2(1):e000143.
2. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, group Fs. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. *Clin Exp Rheumatol*. 2006;24(6 Suppl 43):S-77-82.

3. Bakker MF, Jacobs JW, Welsing PM, van der Werf JH, Linn-Rasker SP, van der Veen MJ, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. *Ann Rheum Dis*. 2010;69(10):1849-52.
4. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet*. 1997;350(9074):309-18.
5. Boers M, van Tuyl L, van den Broek M, Kostense PJ, Allaart CF. Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. *Annals of the rheumatic diseases*. 2013;72(3):406-9.
6. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 1999;17(6):699-704.
7. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. *Ann Rheum Dis*. 2007;66(2):235-41.
8. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. *Annals of the rheumatic diseases*. 2017;76(6):1102-7.
9. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. *Ann Rheum Dis*. 2008;67(5):656-63.
10. Daien CI, Hua C, Combe B, Landewe R. Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. *RMD Open*. 2017;3(1):e000404.
11. de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. *Ann Rheum Dis*. 2013;72(1):72-8.
12. de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. *Ann Rheum Dis*. 2014;73(7):1331-9.
13. Dirven L, van den Broek M, Kroon HM, Grillet BA, Han KH, Kerstens PJ, et al. Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints. *Rheumatology (Oxford)*. 2012;51(12):2262-8.
14. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis*. 1999;58(4):220-5.
15. Ferraz MB, Pinheiro GR, Helfenstein M, Albuquerque E, Rezende C, Roimicher L, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. *Scand J Rheumatol*. 1994;23(5):231-6.

16. Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. *Rheumatology (Oxford)*. 2014;53(11):1984-93.
17. Gaujoux-Viala C, Nam J, Ramiro S, Landewe R, Buch MH, Smolen JS, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the rheumatic diseases*. 2014;73(3):510-5.
18. Gerards AH, Landewe RB, Prins AP, Bruyn GA, Goei The HS, Laan RF, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. *Ann Rheum Dis*. 2003;62(4):291-6.
19. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum*. 2005;52(11):3381-90.
20. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med*. 2007;146(6):406-15.
21. Ghosh B, Halder S, Ghosh A, Dhar S. Early rheumatoid arthritis: clinical and therapeutic evaluation in a tertiary care centre in India. *Indian Journal of Rheumatology*. 2008;3(2):48-51.
22. Giacomelli R, Cipriani P, Matucci Cerinic M, Fulminis A, Barattelli G, Pingiotti E, et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study. *Clin Exp Rheumatol*. 2002;20(3):365-72.
23. Gibson T, Emery P, Armstrong RD, Crisp AJ, Panayi GS. Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis--a comparative study. *Br J Rheumatol*. 1987;26(4):279-84.
24. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet*. 2004;364(9430):263-9.
25. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis*. 2008;67(6):823-8.
26. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. *Ann Rheum Dis*. 2009;68(3):330-6.
27. Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van't Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. *Br J Rheumatol*. 1994;33(11):1049-55.
28. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. *Br J Rheumatol*. 1997;36(10):1082-8.
29. Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJA, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. *The Cochrane database of systematic reviews*. 2016(8):CD010227-CD.

30. Heimans L, Wevers-de Boer KV, Koudijs KK, Visser K, Goekoop-Ruiterman YP, Harbers JB, et al. Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. *Arthritis research & therapy*; 2013;R173.
31. Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. *Ann Rheum Dis*. 2014;73(7):1356-61.
32. Heimans L, Akdemir G, Boer KV, Goekoop-Ruiterman YP, Molenaar ET, van Groenendael JH, et al. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). *Arthritis Res Ther*. 2016;18:23.
33. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. *Arthritis Rheum*. 2006;54(5):1401-9.
34. Karstila KL, Rantalaiho VM, Mustonen JT, Mottonen TT, Hannonen PJ, Leirisalo-Repo M, et al. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. *Clin Exp Rheumatol*. 2010;28(1):73-8.
35. Kauppi MJ, Neva MH, Laiho K, Kautiainen H, Luukkainen R, Karjalainen A, et al. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs. *J Rheumatol*. 2009;36(2):273-8.
36. Kim WU, Cho ML, Kim SI, Yoo WH, Lee SS, Joo YS, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. *J Rheumatol*. 2000;27(2):324-31.
37. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Roday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. *Ann Rheum Dis*. 2011;70(6):1039-46.
38. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. *Arthritis Rheum*. 2004;50(7):2072-81.
39. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 2002;137(9):726-33.
40. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. *Arthritis Rheum*. 2002;46(2):347-56.
41. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. *Arthritis Rheum*. 2005;52(5):1360-70.
42. Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipainen-Seppanen O, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). *Ann Rheum Dis*. 2013;72(6):851-7.

43. Li R, Zhao JX, Su Y, He J, Chen LN, Gu F, et al. High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial. *Medicine (Baltimore)*. 2016;95(28):e3968.
44. Machein U, Buss B, Spiller I, Braun J, Rudwaleit M, Faerber L, et al. Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. *Rheumatology (Oxford)*. 2002;41(1):110-1.
45. Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. *J Rheumatol*. 2007;34(2):316-21.
46. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. *Rheumatology (Oxford)*. 2003;42(12):1545-9.
47. Markusse IM, Dirven L, Gerards AH, van Groenendael JH, Runday HK, Kerstens PJ, et al. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. *Arthritis Res Ther*. 2015;17:232.
48. Mary J, De Bandt M, Lukas C, Morel J, Combe B. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. *The Journal of rheumatology*. 2017;44(6):773-9.
49. Mian AN, Ibrahim F, Scott DL, Galloway J, group Ts. Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient? *Arthritis Res Ther*. 2016;18(1):142.
50. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum*. 2012;64(9):2824-35.
51. Mottaghi P, Karimzade H. Does chloroquine decrease liver enzyme abnormalities induced by methotrexate in patients with rheumatoid arthritis? *Journal of Research in Medical Sciences*. 2005;10(3):135-8.
52. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. *Lancet*. 1999;353(9164):1568-73.
53. Neva MH, Kauppi MJ, Kautiainen H, Luukkainen R, Hannonen P, Leirisalo-Repo M, et al. Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. *Arthritis Rheum*. 2000;43(11):2397-401.
54. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med*. 1996;334(20):1287-91.
55. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2002;46(5):1164-70.
56. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. *N Engl J Med*. 2013;369(4):307-18.
57. Peper SM, Lew R, Mikuls T, Brophy M, Rybin D, Wu H, et al. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. *Arthritis Care Res (Hoboken)*. 2017;69(10):1467-72.

58. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. *Arthritis Rheum.* 2004;50(1):55-62.
59. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. *Arthritis Rheum.* 2005;52(1):36-41.
60. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. *Arthritis Rheum.* 2000;43(8):1809-19.
61. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Jarvenpaa S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. *Arthritis Rheum.* 2009;60(5):1222-31.
62. Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Jarvenpaa S, Hannonen P, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. *Arthritis Res Ther.* 2010;12(3):R122.
63. Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Mottonen T, et al. Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial. *Ann Rheum Dis.* 2013;72(5):786-8.
64. Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppanen O, Mottonen T, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. *Ann Rheum Dis.* 2014;73(11):1954-61.
65. Rau R, Schleusser B, Herborn G, Karger T. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. *J Rheumatol.* 1998;25(8):1485-92.
66. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Cherie-Ligniere EL, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. *Rheumatol Int.* 2005;25(1):15-22.
67. Scott DL, Dawes PT, Tunn E, Fowler PD, Shadforth MF, Fisher J, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. *Br J Rheumatol.* 1989;28(2):128-33.
68. Scott DL, Ibrahim F, Farewell V, O'Keefe AG, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. *BMJ (Clinical research ed.).* 2015;350(8900488, bmj, 101090866):h1046-h.
69. Seegobin SD, Ma MH, Dahanayake C, Cope AP, Scott DL, Lewis CM, et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. *Arthritis Res Ther.* 2014;16(1):R13.

70. Shashikumar NS, Shivamurthy MC, Chandrashekara S. Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis. *Indian J Pharmacol*. 2010;42(6):358-61.
71. Taggart AJ, Hill J, Astbury C, Dixon JS, Bird HA, Wright V. Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. *Br J Rheumatol*. 1987;26(1):32-6.
72. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. *N Engl J Med*. 1995;333(3):137-41.
73. van den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. *Clin Exp Rheumatol*. 2012;30(4 Suppl 73):S35-8.
74. van der Goes MC, Jacobs JW, Jurgens MS, Bakker MF, van der Veen MJ, van der Werf JH, et al. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? *Osteoporos Int*. 2013;24(4):1429-36.
75. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Ann Rheum Dis*. 2007;66(10):1356-62.
76. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. *Ann Rheum Dis*. 2009;68(6):914-21.
77. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet*. 2009;374(9688):459-66.
78. van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet*. 2012;379(9827):1712-20.
79. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis*. 2007;66(11):1443-9.
80. Verstappen SM, Bakker MF, Heurkens AH, van der Veen MJ, Kruize AA, Geurts MA, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. *Ann Rheum Dis*. 2010;69(6):1044-8.
81. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. *Ann Rheum Dis*. 2015;74(1):27-34.
82. Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. *Ann Rheum Dis*. 2017;76(3):511-20.
83. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate

- and leflunomide in patients with active rheumatoid arthritis. *Arthritis Rheum.* 1999;42(7):1322-8.
84. Wijesinghe H, Galappatthy P, de Silva R, Seneviratne SL, Saravanamuttu U, Udagama P, et al. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. *BMC Musculoskelet Disord.* 2017;18(1):310.
85. Willkens RF, Urowitz MB, Stablein DM, McKendry RJ, Jr., Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. *Arthritis Rheum.* 1992;35(8):849-56.
86. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. *Arthritis Rheum.* 1995;38(12):1799-806.